Sheet	1	of	4

FORM PTO-1449

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No.

Serial No. 09/602,812

Applicant

Adams et al. Filing Date

23 Jun 2000

Group To Be Assigned

# LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

### U.S. PATENT DOCUMENTS

Examiner nitials	Document No	umber Date	Name	Class	Subclass	Filing Date
	116 4,753,894		Frankel et al.			
A1-	117 4,935,341		Bargmann et al.			
	118 4,943,533		Mendelsohn et al.			
	119 4,975,278		Senter et al.			
	120 5,169,774	Λ	Frankel et al.			
	121 5,288,477		Bacus, S.			
	122 5,359,046	į –	Capon et al.			
	123 5,367,060		Vandlen et al.			
	124 5,401,638	1	Carney et al.			
	125 5,464,751		Greene et al.			
	126 5,578,482		Lippman et al.			
1	127 5,604,107		Carney et al.			
	128 5,663,144	02.09.97	Greene et al.			
	129 5,705,157		Greene, M. L.		ĺ	
	130 5,720,937		Hudziak et al.		1	
	131 5,720,954	24.02.98	Hudziak et al.			
	132 5,725,856	10.03.98	Hudziak et al.			
	133 5,726,023	10.03.98	Cheever et al.			
	134 5,728,687	1	Bissery, M.			
	135 5,747,261	05.05.98	King et al.			
	136 5,770,195	23.06.98	Hudziak et al.		*	
	137 5,772,997	30.06.98	Hudziak et al.			
	138 5,776,427	07.07.98	Thorpe et al.			
	139 5,801,005	01.09.98	Cheever et al.			
	140 5,834,229	10.11.98	Vandlen et al.	Ì _		
	141 5,837,243	17.11.98	Deo et al.			ĺ
	142 5,837,523	3 17.11.98	Greene et al.		1	
	143 5,840,525	5 24.11.98	Vandlen et al.			
	144 5,846,538	8 08.12.98	Cheever et al.			
	145 5,856,110		Vandlen et al.			
	146 5,859,20	6 12.01.99	Vandlen et al.	]	i	
i	147 5,869,44	5 09.02.99	Cheever et al.			
1	148 5,876,71	2 02.03.99	Cheever et al.			
	149 5,877,30	5 02.03.99	Huston et al.			
11/	150 5,908,83	5 01.06.99	Bissery, M.			
	151 5,910,48		Curiel et al.			
Examir	<del></del>	· L'Helle	~	Date Considered	12/29	103

Sheet 2\_\_\_\_ of

FORM PTO-1449

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. P1467R2

Serial No. 09/602,812

**Applicant** 

Adams et al.

Group

Filing Date 23 Jun 2000 To Be Assigned

# LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## **U.S. PATENT DOCUMENTS**

xaminer nitials		Document Number	Date	Name	Class	Subclass	Filing Date
121+	152	5,922,845	13.07.99	Deo et al.			
1	153	5,939,531	17.08.99	Wels et al.			
	154	5,968,511	19.10.99	Akita et al.		1	
	155	5,977,322	02.11.99	Marks et al.			
	156	5,985,553	16.11.99	King et al.			,
	157	6,015,567	18.01.00	Hudziak et al.			
	158	6,028,059	22.02.00	Curiel et al.			
	159	6,054,297	25.04.00	Carter et al.			
	160	6,054,561	25.04.00	Ring			
- 1	161	6,096,873	01.08.00	Schaefer et al.			
1	162	6,123,939	26.09.00	Shawver et al.			
7	163	6,165,464	26.12.00	Hudziak et al.			

### FOREIGN PATENT DOCUMENTS

Examiner							Transla	ation
Initials		Document Number	Date	Country	Class	Subclass	Yes	No
MIF	164	0,616,812 A1	28.09.94	EPO		}		
1	165	711,565	26.08.98	EPO				
\ \	166	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)				
	167	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)				
	168	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)				ļ
	169	5-117165	14:05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)	]		1	
	170	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			•	
	171	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)				ł
1	172	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)		1		ļ
1	173	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)			ļ	
1	174	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)	-	}		Ì
	175	WO 00/61185	19.10.00	PCT	}		]	
1	176	WO 89/06692	27.07.89	PCT				1
	177	WO 92/10573	25.06.92	PCT		1	Ì	
- 1	178	WO 93/12220	24.06.93	PCT	1		ŀ	
- 1	179	WO 93/21232	28.10.93	PCT .			-	1
	180	WO 93/21319	28.10.93	PCT .	1		ļ	1
ľ	181	WO 94/28127	08.12.94	PCT				
	182	WO 95/16051	15.06.95	PCT	1			
	183	1	29.06.95	PCT				
	184	Į.	26.10.95	PCT				
$\mathbb{V}$								

Examiner

Date Considered

12/24/03

U.S. Dept. of Commerce

Patent and Trademark Office

Serial No. Atty Docket No. 09/602,812 P1467R2

Adams et al. Filing Date

23 Jun 2000

**Applicant** 

Group To Be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

# FOREIGN PATENT DOCUMENTS

Examiner							Transla	
Initials		Document Number	Date	Country	Class	Subclass	Yes	No
AVH	185	WO 96/18409	20.06.96	PCT				
1	186	WO 97/04801	13.02.97	PCT				
	187	WO 97/20858	12.06.97	PCT				
	188	WO 97/27848	07.08.97	PCT				
	189	WO 97/38731	23.10.97	PCT				
	190	WO 98/45479	15.10.98	PCT				
V	191	WO 99/31140	24.06.99	PCT				

		OTHER DISCLOSURES (Including Author, Title, Dat	e, Pertinent Pages, etc.)			
H	192	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with  Chemotherapy Against Human Breast Carcinoma Xenografts" Proceedings of ASCO-13th Annual Meeting  (Abstract #53), Dallas, TX 13:63 (Mar 1994)  Baselga et al., "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic				
	193	implications" <u>Oncology</u> 11(3 Suppl 2):43-48 (Mar 1997)				
	194	Baselga et al., "Monoclonal antibodies directed against growt chemotherapeutic agents" <u>Annals of Oncology</u> (abstract #010) 5	(Suppl. 5) (1994)			
	195	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (He of Paclitaxel and Doxorubicin against HER2/neu Overexpessing Research 58:2825-2831 (July 1998)	Human Breast Cancer Xenografts" <u>Cancer</u>			
	196	De Santes et al., "Radiolabeled Antibody Targeting of the HER 52:1916-1923 (1992)	•			
	197	DiFiore et al., "erbB-2 is a potent oncogene when overexpress 237(4811):178-182 (Jul 10, 1987)				
	198	Drebin et al., "Inhibition of tumor growth by a monoclonal an tumor antigen" Proc. Natl. Acad. Sci. 83:9129-9133 (1986)	•			
	199	Drebin et al., "Monoclonal Antibodies Specific for the neu Or Effects In Vivo" Oncogene 2(4):387-394 (1988)				
	200	Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd (1981)	edition, New York, NY:Wiley pps. 13-17			
	201					
	202	Green et al., "Preclinical Evaluation of WR-151327: An Orally Research 54(3):738-741 (Feb 1, 1994)	•			
	203	Guy et al., "Expression of the neu protooncogene in the mamma metastatic disease" <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 89(22):10578-1	10582 (Nov 15, 1992)			
	204	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Ac</u> 1198(2-3):165-184 (Dec 30, 1994)				
	205	Ilgen et al., "Characterization of anti-HER/2 antibodies which in vitro" Proceedings of the American Association for Cancer	Research (abstract #3209) 37:470 (Mar 19:			
V	206	Masuko et al., "A murine Monoclonal Antibody That Recognizes c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14	an Extracellular Domain of the Human (January 1989)			
Exami	ner	In LA Librar	Date Considered 12/29/03			

Sheet	4	of	4
Officet		Oi	<u> </u>

~~	~~.	DTD	-1449
	$n_{AB}$	P1(1)	_1////

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. Serial No. P1467R2 . 09/602,812

Applicant

Adams et al.

# LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)			Filing Date	Group		
(U	ise sevi	eral sneets il necessary)	23 Jun 2000	To Be Assigned		
		OTHER DISCLOSURES (Including Author, Title, Date, I	Pertinent Pages, etc.)			
411	207	Mendelsohn et al., "Receptor blockade and chemotherapy: a new apannals of Oncology (abstract #040) 7(Suppl. 1):22 (1996)	oproach to combination	on cancer therapy"		
AH	207	Norton, L, "Evolving concepts in the systemic drug therapy of bi	reast cancer" <u>Seminar</u>	s in Oncology 24(4		
	208	Suppl 10):S10-3-S10-10 (Aug 1997)				
	209	Pegram et al., "Inhibitory effects of combinations of HER-2/neu used for treatment of human breast cancers" Oncogene 18:2241-22	51 (1999)			
	210	Raefsky et al., "Phase II Trial of Docetaxel and Herceptin as F Women with Metastatic Breast Cancer Whose Tumors Overexpress HE 18:137a (1999)	R2" <u>Proceedings of As</u>	SCO (Abstract #523)		
	211	Ravdin and Chamness, "The c-erbB-2 proto-oncogene as a prognost cancer: a paradigm for the development of other macromolecular	ic and predictive man markersa review" <u>G</u> e	rker in breast ene 159(1):19-27 (Jun		
	212	14, 1995) Rodeck et al., "Interactions between growth factor receptors and human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)	d corresponding mono	clonal antibodies in		
	213	Schlom, J., "Monoclonal Antibodies: They're More and Less Than Oncology, Broder, S. ed., Baltimore, MD:Williams & Wilkins, Cha	You Think" <u>Molecular</u> pter 6, pps. 95-134	Foundations of (1991)		
	214	Seifert et al., "Dexrazoxane in the prevention of doxorubicin-i Pharmacotherapy 28(9):1063-1072 (Sep 1994)	nduced cardiotoxicit	y" <u>Annals of</u>		
		Singal and Iliskovic, "Doxorubicin-induced cardiomyopathy" New England J. of Medicine 339(13):900-905 (Sep 24, 1998)				
	<del> </del>	Singal et al., "Combination therapy with probucol prevents adriamycin-induced cardiomyopathy" <u>Journal of</u>				
	216	Molecular & Cellular Cardiology 27(4):1055-1063 (Apr 1995)  Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast				
	217	cancer" Proceedings of the American Association for Cancer Rese	<u>earch</u> 37:625-626 (Mar	1996)		
1	218	Zhang et al., "Shared antigenic epitopes and pathobiological fu antibodies" <u>Experimental and Molecular Pathology</u> 67:15-25 (1999	inctions of anti-pi85	merz/med monocional		
		·	-			
	1					
	-					
	ļ					
		·				
Exami		Vinne L'Adlum	<u>t</u>	9/03		
*Exan	niner:	nitial if reference considered, whether or not citation is in conformance with MPEP	609; draw line through c	itation		

if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	1	of	1

FORM PTO-1449	3 JUI	*
1 0111111 10-17-13	3	17. 望
	岜	<i>40)</i> = 3
	à.	٠. ٠
LIST OF DISCLOS	UR <b>EP</b> CII	ED BXAPPLICANT
	UE	MARKO
(Use several sh	eets if nece	essary)

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.
P1467R2

Applicant
Adams et al.

Appli

Filing Date Group
23 Jun 2000 1642

## **U.S. PATENT DOCUMENTS**

U.S. PATENT DOCUMENTS								
xaminer nitials	Document Number	Date	Name	Class	Subclass	Filing Date		
Acit	224 5,804,396	08.09.98	Plowman		The state of the s	12.10.94		
			-					
xaminer	0 4 4 1 0/4	00,		Date Considered	1,21000			

Unnel Hollism

1/17/2003

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT

U.S. Dept. of Commerce Patent and Trademark Office

Serial No. Atty Docket No. 09/602,812 P1467R2

**Applicant** 

Adams et al. Filing Date

23 Jun 2000

Group 1642

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	225	Document Number 6,417,168	Date 09.07.02	Name Greene et al.	Class	JECH CENTER 1600/2000	
Examine	r	<u> </u>	21.00	Dat	te Considered	)c + 21	

FORM PTO-1449

U.S. Dept. of Commerce

Atty Docket No. P1467R2 Patent and Trademark Office

Serial No. 09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant Adams et al.

Filing Date

23 Jun 2000

Group 1642

### **U.S. PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
MK	236	2002/0076695	20.06.02	Ross, J.			
ALH	237	2002/0155527	24.10.02	Stuart et al.			
Art	238	5,514,554	07.05.96	Bacus, S.	Name of Street or other Designation of the last of the		
ALH	239	5,571,894	05.11.96	Wels, W. et al.			
M4	240	5,587,458	24.12.96	King, C. et al.	**************************************	Section Section	
MH	241	5,783,404	21.07.98	Koski, R.	NAME ADDRESS NAME OF TAXABLE		
ALH	242	5,846,749	08.12.98	Slamon et al.	L 2. 1. Marie 1985		
ALH	243	5,856,089	05.01.99	Wang et al.	Marie State	تقسقتند والعري	marrie,
PeH)	244	5,882,864	16.03.99	An et al.	ها دو	=	elta s
Artt	245	5,925,519	20.07.99	Jensen et al.	ten a carrier	15 a 2148	om no reality
ALH	246	5,994,071	30.11.99	Ross et al.	Alley Company	THE TRANSPORT OF A	
AL4	247	6,270,765	07.08.01	Deo et al.	**************	increase and a large	ر شب
AcH	248	6,333,348	25.12.01	Vogel et al.			
ALH	249	6,358,682	19.03.02	Jaffee et al.	ا استعدادی زیران		· <del></del> · "
ALH	250	6,395,272	28.05.02	Deo et al.	مصني معنده		~· <del>***</del>
ALH	251	6,403,630	11.06.02	Dannenberg et al.	market		
PUH	252	6,458,356	01.10.02	Arakawa et al.	B. ()		- 1
AUH	253	6,512,097	28.01.03	Marks et al.			,

### **FOREIGN PATENT DOCUMENTS**

				TOTAL CONTRACT DOOR	EITTO			
Examiner Initials		Document Number	Date	Country	Class	Subclass	Transla Yes	ation No
ALH	254	1,006,194	07.06.00	EPO				
AUL	255	412,116	29.11.95	EPO				
A 1+	256	444,181	31.10.01	EPO	- magazine	and an orași and si a		ers . Jests
A17	257	494,135	10.04.96	EPO	فالتراب يتعاهد وارتعاد الألا	s and the same of the same	es. marrar ()	
4rH	258	502,812	14.08.96	EPO	William II. 1 F T F T SEPS F T	ila a menageage est	Acceptance Acceptance	
ALIT	259	554,441	27.01.99	EPO	Section 25 and Addison con-			
alt	260	656,367	07.06.95	EPO			**	>
Mult	261	WO 01/05425	25.01.01	PCT	K 2			-
nut	262	WO 01/09187	08.02.01	PCT	• •			
Alt	263	WO 01/20033	22.03.01	PCT	•			
MH	264	WO 01/21192	29.03.01	PCT		<del></del>		
ALH	265	WO 01/32155	10.05.01	PCT				
ALH	266	WO 87/07646	17.12.87	PCT			amerikas. ~	
MIT		WO 89/10412	02.11.89	PCT		OMETICAL PROPERTY A	-	
ALH	268	WO 91/02062	21.02.91	PCT			And the same of th	,
Evamina				L				

Examiner

Date Considered



Examiner

FORM PTO-1449

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. Dept. of Commerce

Patent and Trademark Office

Atty Docket No. Serial No. 09/602,812

Applicant

Date Considered

Adams et al.

Filing Date
23 Jun 2000

Group 1642

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translat Yes	ion No
ALH	269	WO 91/05264	18.04.91	PCT			er anns an e	
/AUH	270	WO 93/03741	04.03.93	PCT	Margara			
ALIT	271	WO 93/16185	19.08.93	PCT	ودر در و متناستمرد	* - · · · · · · · · · · · · · · · · · ·	5	
ALH	272	WO 96/07321	14.03.96	PCT				
ALH	273	WO 96/16673	06.06.96	PCT				
AH	274	WO 96/40789	19.12.96	PCT	L	,	4	
AH	275	WO 97/00271	03.01.97	PCT	1		, ,	
A14	276	WO 98/02463	22.01.98	PCT			. ,	
AH	277	WO 98/16628	23.04.98	PCT				
A214	278	WO 98/18489	07.05.98	PCT	· ·	·		
ALH		WO 98/33914	06.08.98	PCT				
Art	280	WO 99/55367	04.11.99	PCT	Milan and the			

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

1	OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)								
ALIH	281	Agus at al., "Differential Anti-Tumor Effects of Targeting Distinct Epitopes of the Her-2/neu Extracellular Domain in Xenograft Models of Prostate Cancer." <u>Proceedings of the American Association</u>							
		for Cancer Research Annual Meeting (Abstract #4570) 41:719 (Mar 2000)							
1		Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-Dependent and							
MH	282	-Independent Human Xenograft Models" <u>Cancer Research</u> 59:4761-4764 (1999)							
i e	<del></del>	American Cancer Society Textbook of Clinical Oncology, Murphy et al., 2nd edition, Atlanta:American							
ACH	283	Cancer Society pps. 126-127 (1995)							
		Ching, K., "Role of c-erb B gene family in prostate cancer" Dissertation Abstracts International							
PRH	284	55(11):4738-B (May 1995)							
<del></del>		Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" Cancer Immunology and							
ALH	205	Immunotherapy 45(3-4):210-215 (Nov-Dec 1997)							
INU	285	15(5 1, 1216 125 (No. 200 137),							
		Curti, B., "Physical barriers to drug delivery in tumors" Critical Reviews in Oncology-Hematology							
My	286	14(1):29-39 (Feb 1993)							
1100	200								
		Ezeh et al., "Differential activation of ErbB receptors in the rat olfactory mucosa by transforming							
AH		growth factor-α and epidermal growth factor in vivo" <u>Journal of Neurobiology</u> 37(2):199-210 (Nov 5, 1998)							
<u> </u>		Gibson et al., "A novel method for real time quantitative RT-PCR" Genome Research 6(10):995-1001 (Oct							
l an il	288								
MH									
7		Gura, T., "Systems for identifying new drugs are often faulty" Science 278(5340):1041-1042 (Nov 7, 1997)							
MH	289								
TILL	200								
		Heid et al., "Real time quantitative PCR" Genome Research 6(10):986-994 (1996)							
ALH	290								
100	250								
		Jain, R., "Barriers to drug delivery in solid tumors" Scientific American 271(1):58-65 (Jul 1994)							
Alt	291								
a but									
. ,		James et al., "Phase II Trial of the Bispecific Antibody MDX-H210 (anti-Her2/Neu X anti-CD64) Combined							
AH	292	With GM-CSF in Patients With Advanced Prostate and Renal Cell Carcinoma That Express Her2/Neu." British							
1711		Journal of Cancer (Abstract #56) 78:19 (1998)							

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609: draw line through citation

Sheet 3 of 3

FORM	PTO-	1449	U.S. Dept. of Commerce	Atty Docket No.	Senai No.					
			Patent and Trademark Office	P1467R2	09/602,812					
LIST	OF DI	SCLOSURES CITED BY APPLICANT	- <del> </del>	Applicant Adams et al.						
(L	lse sev	veral sheets if necessary)		Filing Date	Group					
`	,00	oral orionto il rioccessi,		23 Jun 2000	1642					
			Pertinent Pages, etc.)							
ANT	293	James et al., "Phase II trial of the bispecific antibody MDX-H210 (anti-HER2/NEU X anti-CD64) combastion of the bispecific antibody MDX-H210 (anti-HER2/NEU X anti-CD64) combastic GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/NEU" Property Manual Meet. Soc. Clin. Oncol. (Abstract No. 1681) 17:436a (1988)								
ALH	*294	Kabat. <u>Sequences of Proteins of Immunological Interest</u> , US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)								
14	295	Knox et al., "Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma"  Clinical Cancer Research 2(3):457-470 (Mar 1996)								
All	296	Medarex, Inc., "Medarex's HER-2 studies" (company press release)	(May 19, 1998)							
MH	297	Myers et al., "Intracellular ant prostatic cells" <u>Proceedings of</u> #2334) 37:342 (1996)	the American Association for Ca	ncer Research Annual	Meeting (Abstract					
All	298	Nagabhushan et al., "CWR22: The and Relapsed Strains Both in Viv	o and in Soft Agar" Cancer Rese	arch 56:3042-3046 (1	.996)					
MH	299	Nagy et al., "Complexity of sign receptor-targeted cancer therapy	<del>_</del>	_	ential of					
AH	300	Okabayashi et al., "Podofilox-induced regression of Shope papillomas may be independent of host immunity" <u>Journal of Investigative Dermatology</u> 101(6):852-857 (Dec 1993)								
A214	301	Okuda et al., "The cytostome of Trypanosoma cruzi epimastigotes is associated with the flagellar complex" <u>Experimental Parasitology</u> 92(4):223-231 (Aug 1999)								
ALL	302	Sato et al., "A Metastatic and A Inoculation of LNCaP Cells in SC		_	Intraprostatic					
MH	303	_	Skrepnik et al., "Recombinant Oncotoxin AR209 (anti-p185 <sup>erbB-2</sup> ) Diminishes Human Prostate Carcinoma Xenografts" <u>Journal of Urology</u> 161:984-989 (1999)							
AH	304	Stearns et al., "Workgroup 2: Hu	man Xenograft Models of Prostate	e Cancer" <u>Prostate</u> 3	6:56-58 (1998)					
MH	305	Wainstein et al., "CWR22: Androgen-dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma" <u>Cancer Research</u> 54:6049-6052 (1994)								
					,					
Examiner		anne L Holling	Da	ite Considered	1 03					
*Examine	er: Initi n confo	ial if reference considered, whether or no ormance and not considered. Include copy	t citation is in conformance with MPEP 6	609; draw line through cit o applicant.	ation					